Navigation Links
Neurochem announces departure of Dr. Philippe Calais, President, Global Business
Date:11/30/2007

LAVAL, QC, Nov. 30 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announces the departure of Philippe Calais, PhD. Pharm., Neurochem's President, Global Business. Dr. Calais joined Neurochem in 2003, and is leaving effective December 31, 2007, to pursue other interests.

"Dr. Calais has made a significant contribution to creating constructive relationships for Neurochem in international markets and we are grateful for having had the benefit of his expertise during the five years he has been with us," said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO. "We wish him every success in his new pursuits."

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to patients suffering from serious diseases.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 877 680-4500 or visit the Web Site at: http://www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on the forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise. Please see the Annual Information Form for further risk factors that might affect the Company and its business.

For further information, please contact:

Lise Hebert, Ph.D. Tel: 1-450-680-4572

Vice President, Corporate Communications lhebert@neurochem.com


'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Neurochem reports results for third quarter of fiscal 2007
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... , ... “I Forgive You”: a fine examination of how God handles sin, including how ... published author, Stephen Miller, who, for over ten long years has been waiting to release ... Trinidad and Tobago, he has been serving the Lord for over twenty years, and he ...
(Date:1/20/2017)... ... ... in Suffolk”: a story of love, secrets, and mystery. “Christmas in Suffolk” is ... works in a daycare and looks for inspiration in the local coffee shop as ... Seymour’s new book is an adventure of love and secrets. , After ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Knowledge is God’s ... guided by faith. “Knowledge is God’s Lighthouse” is the creation of published author, Gene ... novels, and poetry collections. , “I have been writing since high school and ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All ... is the creation of published author, Keith C. A. Tucker, son of Minister Delores ... World Outreach pastured by Reverend Mark Hardy , “While sitting up in bed, I ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... On-demand E-learning system for Clinical and Regulatory education for Physicians, Physician Advisors, ... Aerolib`s successful education methodology of Disease Specific Documentation Improvement. , The Aerolib ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017  Today, during ... Conference, "PI3K Pathways in Immunology, Growth Disorders ... (NASDAQ: INFI ) presented preclinical ... candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical ... help overcome resistance to checkpoint inhibition by ...
(Date:1/20/2017)... Jan 20, 2017 Research and Markets ... Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales ... their offering. ... Global Hearing Aids Market Sales Volume, Company Analysis and ... high-growth hearing aid industry. The growing prevalence of ...
(Date:1/20/2017)...  Palladian Health, a leading provider of quality ... an opioid management program which assists physicians in ... stem the growing tide of dependence on prescription ... non-cancer pain (back pain, neck pain, and degenerative ... evidence regarding long-term effectiveness. The new ...
Breaking Medicine Technology: